OMEROS CORP
OMEROS CORP
Aktie · US6821431029 · OMER · A0NBFF (XNMS)
Übersicht Finanzkennzahlen
3,37 USD
-5,07 % -0,18 USD
NASDAQ/NMS (GLOBAL MARKET) (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 21:44

Aktuelle Kurse von OMEROS CORP

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
OMER
USD
13.06.2025 21:44
3,37 USD
3,56 USD
-5,20 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % -12,24 % -14,25 % -59,98 % -55,83 % -16,99 % -76,98 %

Firmenprofil zu OMEROS CORP Aktie

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Investierte Fonds

Folgende Fonds haben in investiert: OMEROS CORP investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
35,46
Anteil (%)
0,08 %

Unternehmensdaten

Name OMEROS CORP
Firma Omeros Corporation
Symbol OMER
Website https://www.omeros.com
Heimatbörse XNMS NASDAQ/NMS (GLOBAL MARKET)
WKN A0NBFF
ISIN US6821431029
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Gregory A. Demopulos M.D.
Marktkapitalisierung 386 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,2 T
Adresse The Omeros Building, 98119 Seattle
IPO Datum 2009-10-08

Ticker Symbole

Name Symbol
Frankfurt 3O8.F
NASDAQ OMER

Weitere Aktien

Investoren die OMEROS CORP die halten, haben auch folgende Aktien im Depot:
AMGEN INC
AMGEN INC Aktie
ASTRAZENECA PLC
ASTRAZENECA PLC Aktie
AUTODESK INC
AUTODESK INC Aktie
BIOGEN INC
BIOGEN INC Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
EBAY INC
EBAY INC Aktie
ESSEX PROPERTY TRUST
ESSEX PROPERTY TRUST Fonds
INTEL CORP
INTEL CORP Aktie
JPMorgan Diversified Fund Class A
JPMorgan Diversified Fund Class A Fonds
MICROSOFT CORP
MICROSOFT CORP Aktie
O'REILLY AUTOMOTIVE INC
O'REILLY AUTOMOTIVE INC Aktie
Two Harbors Investment Corp.
Two Harbors Investment Corp. Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025